

Special Issue

Cancer Chemoresistance

Message from the Guest Editor

In line with numerous other therapeutic agents, the success of cancer drugs is hindered by the development of clinical drug resistance. The scientific community has mounted a considerable effort in order to understand the underlying mechanisms associated with anticancer drug resistance, over a number of decades. These lines of enquiries have resulted in an enrichment of our knowledge of tumour cell biology—but still leave the oncologist with the day-to-day problem of clinical drug resistance. The overall objective for the cancer scientist is to work hand in hand with the oncologist to find ways to predict in advance clinical drug resistance by the use of biomarker development and also to develop strategies to overcome overt drug resistance for example by the use of combination therapies.

Guest Editor

Dr. Helen M. Coley

Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK

Deadline for manuscript submissions

closed (15 October 2018)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/12734

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)